The pharmaceutical conglomerates are among the participants in DVS Science's series A funding, which has raised $14.6m.
Pfizer Venture Investments and the Roche Venture Fund, the corporate venturing units of drugs companies Pfizer and Roche, are among the investors in Canada-based analytical instrument manufacturer DVS Sciences’ $14.6m series A round.
Roche and Pfizer were joined in the round by US-based venture capital firms 5AM Ventures and Mohr Davidow, along with the Ontario Institute for Cancer Research.
DVS Sciences, which was founded in 2004 as a spin-off from the University of Toronto, will use the proceeds…
